Next-generation companion diagnostics: promises, challenges, and solutions.
作者信息
Khoury Joseph D, Catenacci Daniel V T
机构信息
From the Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston (Dr Khoury); and the Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois (Dr Catenacci).
出版信息
Arch Pathol Lab Med. 2015 Jan;139(1):11-3. doi: 10.5858/arpa.2014-0063-ED.
Abstract
摘要
相似文献
1
Next-generation companion diagnostics: promises, challenges, and solutions.
Arch Pathol Lab Med. 2015 Jan;139(1):11-3. doi: 10.5858/arpa.2014-0063-ED.
2
Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
Expert Rev Mol Diagn. 2020 Jun;20(6):601-610. doi: 10.1080/14737159.2020.1728256. Epub 2020 Feb 17.
3
The evolving potential of companion diagnostics.
Scand J Clin Lab Invest Suppl. 2016;245:S22-5. doi: 10.1080/00365513.2016.1206444. Epub 2016 Jul 19.
4
Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Expert Rev Mol Diagn. 2020 Jun;20(6):637-644. doi: 10.1080/14737159.2020.1743177. Epub 2020 Mar 19.
5
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11.
6
Advanced Companion Diagnostics Facilities: Opportunity Favors the Prepared Laboratory.
Arch Pathol Lab Med. 2015 Oct;139(10):1201. doi: 10.5858/arpa.2015-0095-LE.
7
Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Scand J Clin Lab Invest Suppl. 2016;245:S84-91. doi: 10.1080/00365513.2016.1210331. Epub 2016 Aug 17.
8
Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
Virchows Arch. 2017 Aug;471(2):235-242. doi: 10.1007/s00428-017-2153-8. Epub 2017 May 27.
9
Next-generation sequencing of cancer genomes: lessons learned.
Future Oncol. 2021 Nov;17(31):4041-4044. doi: 10.2217/fon-2021-0764. Epub 2021 Aug 25.
10
Managing the genomic revolution in cancer diagnostics.
Virchows Arch. 2017 Aug;471(2):175-194. doi: 10.1007/s00428-017-2175-2. Epub 2017 Jun 21.
引用本文的文献
1
Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Curr Oncol. 2021 Dec 11;28(6):5278-5294. doi: 10.3390/curroncol28060441.
2
Companion Diagnostics: State of the Art and New Regulations.
Biomark Insights. 2021 Oct 11;16:11772719211047763. doi: 10.1177/11772719211047763. eCollection 2021.
3
Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions.
Cancers (Basel). 2021 Jun 14;13(12):2974. doi: 10.3390/cancers13122974.
4
Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.
Curr Hematol Malig Rep. 2019 Oct;14(5):358-367. doi: 10.1007/s11899-019-00532-w.
5
Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria.
Curr Hematol Malig Rep. 2018 Dec;13(6):467-476. doi: 10.1007/s11899-018-0483-5.
6
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.
Clin Cancer Res. 2018 Feb 1;24(3):521-531. doi: 10.1158/1078-0432.CCR-17-1597. Epub 2017 Aug 24.
7
Cancer diagnostics: The journey from histomorphology to molecular profiling.
Oncotarget. 2016 Sep 6;7(36):58696-58708. doi: 10.18632/oncotarget.11061.
8
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
Gastric Cancer. 2016 Oct;19(4):1066-1079. doi: 10.1007/s10120-015-0566-0. Epub 2015 Nov 18.
9
Companion diagnostics for the targeted therapy of gastric cancer.
World J Gastroenterol. 2015 Oct 21;21(39):10948-55. doi: 10.3748/wjg.v21.i39.10948.
10
Expansion platform type II: testing a treatment strategy.
Lancet Oncol. 2015 Oct;16(13):1276-8. doi: 10.1016/S1470-2045(15)00224-7. Epub 2015 Sep 3.
本文引用的文献
1
A cancer trial scandal and its regulatory backlash.
Nat Biotechnol. 2014 Jan;32(1):27-31. doi: 10.1038/nbt.2792.
2
First FDA authorization for next-generation sequencer.
N Engl J Med. 2013 Dec 19;369(25):2369-71. doi: 10.1056/NEJMp1314561. Epub 2013 Nov 19.
3
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.
4
Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Clin Cancer Res. 2012 Feb 1;18(3):619-24. doi: 10.1158/1078-0432.CCR-11-2017.
Zotero 插件